MedPath

Amgen

Ownership
-
Employees
26.7K
Market Cap
-
Website
Introduction

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Clinical Trials

887

Active:885
Completed:2

Trial Phases

2 Phases

Phase 1:539
Phase 3:2

Drug Approvals

22

FDA:22

Drug Approvals

Riabni

Approval Date
Jun 16, 2025
FDA

Kanjinti

Approval Date
Mar 22, 2024
FDA

Prolia

Approval Date
Mar 8, 2024
FDA

BLINCYTO

Approval Date
Feb 13, 2024
FDA

AMJEVITA

Approval Date
Feb 5, 2024
FDA

XGEVA

Approval Date
Jan 12, 2024
FDA

LUMAKRAS

Approval Date
Oct 12, 2023
FDA

Otezla

Approval Date
Sep 20, 2023
FDA

REPATHA

Approval Date
Jun 7, 2023
FDA

AIMOVIG

Approval Date
May 16, 2023
FDA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

Distribution across different clinical trial phases (541 trials with phase data)• Click on a phase to view related trials

Phase 1
539 (99.6%)
Phase 3
2 (0.4%)
No trials found

News

QureBio Secures $14 Million Series C1 Funding to Advance Bispecific Antibody Pipeline

QureBio completed a Series C1 financing round raising nearly CNY 100 million (approximately USD 14 million) led by Efung Capital to accelerate clinical trials of its novel antibody therapeutics.

Protein Therapeutics Market Surges to $400 Billion as 20 New Drugs Gain Approval in 2023

The global protein therapeutics market reached an estimated $400 billion in value, driven by increasing pharmaceutical company investment in advanced protein-based drug development strategies.

Racial Disparities Persist in Triple-Negative Breast Cancer Trials Despite Treatment Advances

• Black women face disproportionate burden of triple-negative breast cancer with higher incidence and mortality rates, yet comprise only 6.5% of clinical trial participants versus 14.4% US population representation. • Recent advances in small cell lung cancer treatment include promising DLL3-targeting therapy tarlatamab-dlle, offering new hope for patients with disease progression after platinum-based chemotherapy. • FDA's approval of fam-trastuzumab deruxtecan-nxki marks significant progress in site-agnostic cancer therapy, demonstrating efficacy across multiple HER2-positive solid tumors.

BridgeBio's Attruby Approved for ATTR-CM, Cassava's Simufilam Fails in Alzheimer's Trial

BridgeBio Pharma's Attruby (acoramidis) receives FDA approval for transthyretin amyloidosis cardiomyopathy (ATTR-CM), reducing cardiovascular death and hospitalization.

Combination Immunotherapy Strategies Show Promise in Overcoming NSCLC Treatment Resistance

Combination immunotherapies demonstrate superior efficacy compared to monotherapy approaches in NSCLC, with dual checkpoint inhibition and chemo-immunotherapy combinations showing improved overall survival and progression-free survival rates.

Merck Launches First Phase 3 Program for Oral PCSK9 Inhibitor MK-0616 to Treat High Cholesterol

Merck has initiated the first Phase 3 clinical program for an oral PCSK9 inhibitor, MK-0616, marking a potential breakthrough in cholesterol treatment with a once-daily pill format.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.